💡 Outstanding publication by Eva Valentina Klocker, Daniel Egle, Rupert Bartsch, Gabriel Rinnerthaler and Michael Gnant on the efficacy and safety of CDK4/6 inhibitors in HR+/HER2− early breast cancer. 📖 #ABCSG #BreastCancerResearch #ClinicalTrials

These results demonstrate that such a regimen is both effective and safe and represent a further step forward in the development of de-escalation strategies for the treatment of early breast cancer. Congratulations to Gabriel Rinnerthaler and the entire team 👏 #DeEscalation

👉 Full article: ESMO Open, Volume 10, Issue 1, January 2025, 104096 @MichaelGnant @ElisaAgostinett Another successful PALLAS publication originating from external research proposals – and we’re optimistic that many more will follow soon! 🌟

These insights contribute to the growing body of evidence on the potential role of biomarker-driven optimized treatment strategies with antibody-drug conjugates like T-DXd and HER3-DXd. 💡 #ABCSGbefirst #BreastCancer #CancerResearch #ClinicalTrials #Oncology #HER2 #HER3 #ADCs

The #ABCSG sends you and your loved ones warm wishes for a joyful festive season and a prosperous New Year! 🎄🎉 May the year ahead bring you happiness, good health, and many positive moments. 🍀✨ #HappyHolidays #ProsperousNewYear

The #ABCSG provided regulatory coordination for the trial sites in Austria, with M. Knauer and R. Reitsamer contributing as co-authors to this publication - a testament to ABCSG's important role in advancing breast cancer research within this large-scale int. collaboration.